Jill Wechsler

Jill Wechsler is ACT's Washington Editor

Articles

The Next Big COVID Challenge: Vaccines for Children Under 12

September 21, 2021

If the debate over vaccines for adults and the need for extra booster shots has been heated, FDA will face even more scrutiny over the safety and value of vaccinating children under age 12.

Vaccine Booster Battle Reveals Rifts Among Regulators, Sponsors

September 20, 2021

FDA’s Vaccines and Related Biological Products Advisory Committee announces its recommendations for the authorization of a third dose of the Pfizer/BioNTech Comirnaty vaccine.

Pharma Blocks Democrats’ Drug Pricing Plan

September 17, 2021

Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations.

FDA Moves to Advance Innovative Excipients

September 14, 2021

FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics.

Biden Bolsters Vaccine Production in Pandemic Preparedness Plan

September 10, 2021

White House officials recently announced a nearly $3 billion program to ramp up production of vaccines and their components to better serve patients in the U.S. and globally.

Will Price Controls Limit Drug Development? The Debate Heats Up.

September 02, 2021

A report from the bipartisan Congressional Budget Office analyzes how drug pricing policies could reduce the number of new therapies coming to market.

Pfizer Vaccine Approval Key to Boosting Vaccination Rates

August 24, 2021

The first COVID-19 vaccine, Comirnaty, has received FDA approval. How will vaccination rates be effected?

FDA User Fees To Rise–and Fall–as New Fee Agreements Move Forward

August 20, 2021

While biopharma companies will pay more than $3 million to file an NDA or BLA application during fiscal year 2022, new fees for generic drugs will see modest or no increases and those for biosimilars may drop or hold even.

Biden Highlights Drug Pricing Reforms to Advance Legislative Agenda

August 13, 2021

The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden.